TCL Archive Study Finds 4-20% Of Those With HTLV-3 Develop AIDs Within 32 Months Or Less August 2, 1985
TCL Archive Two-Year Remission While Taking Gleevec Puts Patients Into Normal Mortality Rate March 25, 2011